Các bài viết có thể truy cập công khai - Lowell L HartTìm hiểu thêm
Không có ở bất kỳ nơi nào: 2
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ...
Journal of Clinical Oncology 39 (21), 2375-2385, 2021
Các cơ quan ủy nhiệm: Susan G. Komen
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH)(TBCRC033: ATEMPT Trial)
KJ Ruddy, Y Zheng, N Tayob, J Hu, CT Dang, DA Yardley, SJ Isakoff, ...
Breast Cancer Research and Treatment 189 (1), 103-110, 2021
Các cơ quan ủy nhiệm: Susan G. Komen
Có tại một số nơi: 15
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind …
RS Herbst, R Ansari, F Bustin, P Flynn, L Hart, GA Otterson, G Vlahovic, ...
The Lancet 377 (9780), 1846-1854, 2011
Các cơ quan ủy nhiệm: US National Institutes of Health
Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a …
KA Autio, R Dreicer, J Anderson, JA Garcia, A Alva, LL Hart, MI Milowsky, ...
JAMA oncology 4 (10), 1344-1351, 2018
Các cơ quan ủy nhiệm: US National Institutes of Health
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer
J Berlin, JC Bendell, LL Hart, I Firdaus, I Gore, RC Hermann, MF Mulcahy, ...
Clinical Cancer Research 19 (1), 258-267, 2013
Các cơ quan ủy nhiệm: US National Institutes of Health
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer
AA Chiappori, T Kolevska, DR Spigel, S Hager, M Rarick, S Gadgeel, ...
Annals of oncology 26 (2), 354-362, 2015
Các cơ quan ủy nhiệm: US National Institutes of Health
Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor–positive, node-positive early breast cancer: Final …
I Smith, D Yardley, HA Burris, R De Boer, D Amadori, K McIntyre, ...
Journal of clinical oncology 35 (10), 1041-1048, 2017
Các cơ quan ủy nhiệm: National Institute for Health Research, UK
Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
JT Beck, GN Hortobagyi, M Campone, F Lebrun, I Deleu, HS Rugo, ...
Breast cancer research and treatment 143, 459-467, 2014
Các cơ quan ủy nhiệm: US National Institutes of Health
Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy …
A Forero‐Torres, JR Infante, D Waterhouse, L Wong, S Vickers, ...
Cancer medicine 2 (6), 925-932, 2013
Các cơ quan ủy nhiệm: US National Institutes of Health
Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)
A Bardia, SA Hurvitz, A DeMichele, AS Clark, A Zelnak, DA Yardley, ...
Clinical Cancer Research 27 (15), 4177-4185, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health
Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT
HS Hochster, A Grothey, L Hart, K Rowland, R Ansari, S Alberts, ...
Annals of oncology 25 (6), 1172-1178, 2014
Các cơ quan ủy nhiệm: US National Institutes of Health, UK Medical Research Council
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours
D Mahalingam, MR Patel, JC Sachdev, LL Hart, N Halama, ...
British journal of clinical pharmacology 86 (9), 1836-1848, 2020
Các cơ quan ủy nhiệm: US National Institutes of Health
A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild …
C Eng, A Bessudo, LL Hart, A Severtsev, O Gladkov, L Müller, MV Kopp, ...
International journal of cancer 139 (1), 177-186, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
P Grivas, A Mortazavi, J Picus, NM Hahn, MI Milowsky, LL Hart, A Alva, ...
Cancer 125 (4), 533-540, 2019
Các cơ quan ủy nhiệm: US National Institutes of Health
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
A Wardley, J Cortes, L Provencher, K Miller, AJ Chien, HS Rugo, ...
Breast cancer research and treatment 187, 155-165, 2021
Các cơ quan ủy nhiệm: National Institute for Health Research, UK
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
C Paoletti, MM Regan, SM Niman, EM Dolce, EP Darga, MC Liu, ...
NPJ Breast Cancer 7 (1), 77, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033 …
R Barroso-Sousa, P Tarantino, N Tayob, C Dang, DA Yardley, SJ Isakoff, ...
NPJ Breast Cancer 8 (1), 18, 2022
Các cơ quan ủy nhiệm: US National Institutes of Health, Susan G. Komen
Chương trình máy tính sẽ tự động xác định thông tin xuất bản và thông tin về nhà tài trợ